Several studies have confirmed high levels of vascular endothelial growth factor (VEGF) in
eyes with neovascular glaucoma (NVG). The role of VEGF inhibitors in regression of other
neovascular disorders such as wet-type age-related macular degeneration and diabetic macular
edema has been described. We aim to evaluate the effect of three intravitreal injections of
bevacizumab (Avastin) 2.5 mg versus a sham procedure for treatment of NVG. Outcome measures
include intraocular pressure and extent of iris neovascularization. Both study arms will
receive conventional treatment for NVG.